logo
Warm home discount to be extended to 2.7 million more households

Warm home discount to be extended to 2.7 million more households

Yahoo5 hours ago

Energy bill discounts of £150 will be extended to another 2.7 million households to help with fuel costs next winter.
This brings the number of households eligible for the warm home discount up to just over 6 million, the Department for Energy Security and Net Zero (DESNZ) has confirmed after a consultation.
The changes remove some restrictions on eligibility and mean every bill payer on means-tested benefits will qualify.
Some 900,000 families with children and 1.8 million homes in fuel poverty are set to benefit from the payment.
Prime Minister Keir Starmer said: 'I know families are still struggling with the cost of living, and I know the fear that comes with not being able to afford your next bill.
'Providing security and peace of mind for working people is deeply personal to me as Prime Minister and foundational for the Plan for Change.
'I have no doubt that, like rolling out free school meals, breakfast clubs and childcare support, extending this £150 energy bills support to millions more families will make a real difference.'
Energy Secretary Ed Miliband said: 'Millions of families will get vital support with the cost of living this coming winter, demonstrating this government's commitment to put money in people's pockets through our Plan for Change.
The Conservatives criticised the move, saying energy prices are expected to keep climbing overall.
Andrew Bowie, the acting shadow energy secretary, said: 'Labour promised to cut everyone's energy bills by £300 but they have increased by £280 and are forecast to keep going up.
'Energy bills need to come down but this announcement will cut bills for just a quarter of households whilst increasing them for everyone else.
'Kemi Badenoch and I have been clear that net zero by 2050 is impossible without bankrupting Britain and making hard-working families worse off.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Botani Introduces Premium Tea Leaf Wrappers
Botani Introduces Premium Tea Leaf Wrappers

Yahoo

time21 minutes ago

  • Yahoo

Botani Introduces Premium Tea Leaf Wrappers

The new botanical papers are a coveted natural alternative to hemp, offering superior sensory attributes and smoke-ability for an elevated consumer experience Botani Tea Wrapper LUXEMBOURG, June 19, 2025 (GLOBE NEWSWIRE) -- Botani, the B2B market brand of SWM International and a leader in premium hemp and botanical solutions, today announced the expansion of its botanical wrapper portfolio with the introduction of Botani Tea Wrappers. Meticulously crafted from real tea leaves, these new wrappers deliver an unparalleled smoking experience that complements Botani's existing line of hemp-based papers. "Our new Botani Tea Wrappers showcase the intersection of flower-based materials and artisanal papermaking," said Alex Boone, Managing Director at Botani and VP/GM at SWM International. "Building on our legacy of transforming hemp into superior smoking accessories, we've harnessed the unique properties of tea to develop a wrapper that excels in aroma, flavor, visual appeal and overall smoke-ability." Botani Tea Wrappers provide a versatile option for multiple end-use applications, including cones, blunts, cannagars, and booklets. Like Botani's hemp papers, the tea wrappers are fully customizable, with a wide array of flavor infusions and branding options available. This allows cannabis brands to create highly differentiated products to stand out in an increasingly competitive marketplace. 'Hemp has always been at the heart of our business, and we're constantly innovating to offer versatile solutions for our customers,' said Thomas Kraker, Product Manager at Botani. 'Our tea leaf papers provide a unique and high-quality option that allows brands to expand their product lines while maintaining Botani's renowned commitment to excellence.' Botani's foray into tea wrappers is a natural progression, leveraging SWM International's centuries of expertise in reconstituting botanical materials into specialty papers. The proprietary process results in wrappers that are not only smooth-burning and flavorful, but also easy to package, store and ship. This empowers brands to seamlessly integrate tea wrappers into their existing production lines for maximum efficiency and scalability. About BotaniBotani is the cannabis-specific arm of SWM International, a papermaking pioneer with over 400 years of experience in innovation. The company embodies SWM International's unwavering innovative spirit and dedication to technical progression, embracing cutting-edge papermaking advancements to nurture customer growth with every step. From natural leaf and botanicals to colorful, scented, premium, one-of-a-kind papers, Botani redefines premium natural fibers product manufacturing with customizable and scalable offerings for businesses looking to deliver an elevated consumer experience. For more information, visit For more information or to schedule an interview, please contact Bree DeVita at bree@ or 303-513-1244 A photo accompanying this announcement is available at in to access your portfolio

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy

Yahoo

time21 minutes ago

  • Yahoo

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy

Presented at EACR 2025, promising results show the impact of Brenus Pharma and InSphero's collaboration in advancing translational immunotherapy through scalable 3D tumor models. LISBON, Portugal, June 19, 2025--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus' lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010's therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed by monocyte-derived dendritic cells (mMo-DCs), activating CD8+ T cells. These T cells induced apoptosis in both 2D and 3D colorectal cancer models and released anti-tumor cytokines (IFNγ and Granzyme B). These data reinforce the therapeutic potential of STC-1010. "This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates." Benoit Pinteur, CSO of Brenus Pharma. "We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality." Jan Lichtenberg, CEO of InSphero. About Brenus Pharma Brenus Pharma unlocks the potential of immuno-oncology by generating first-in-class immunotherapies that initiate a multi-specific in vivo immune response against tumors. Their proprietary "off-the-shelf" Stimulated-tumor-Ghost-Cells (SGC) platform mimics patients' tumor cells and makes them visible to the immune system to anticipate, target, and destroy these cells as they appear. Brenus aims to shift the oncology paradigm by making patients active participants in their treatment. About InSphero InSphero sets the standard for in vitro drug discovery and safety testing with innovative 3D cell-based technology and comprehensive preclinical research solutions. Its reliable, scalable and reproducible suite of 3D InSight™ Platforms for Liver Safety, Liver Disease, Islet Biology, and Oncology & Immunology are used by the top pharmaceutical companies worldwide. Learn more at View source version on Contacts contact@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store